Arlington Partners’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-3,445
| Closed | -$270K | – | 37 |
|
|
2026
Q2 | $270K | Buy |
3,445
+749
| +28% | +$60.4K | 0.49% | 26 |
|
|
2026
Q1 | $234K | Buy |
+2,696
| New | +$258K | 0.47% | 56 |
|
|
2025
Q4 | – | Sell |
-54,158
| Closed | -$5.16M | – | 34 |
|
|
2025
Q3 | $5.16M | Buy |
54,158
+2,296
| +4% | +$211K | 1.78% | 16 |
|
|
2025
Q2 | $4.52M | Buy |
51,862
+2,317
| +5% | +$196K | 1.67% | 23 |
|
|
2025
Q1 | $4.45M | Buy |
49,545
+10,586
| +27% | +$947K | 1.75% | 23 |
|
|
2024
Q4 | $3.11M | Sell |
38,959
-10,232
| -21% | -$886K | 1.21% | 48 |
|
|
2024
Q3 | $4.43M | Buy |
49,191
+9,643
| +24% | +$811K | 1.73% | 16 |
|
|
2024
Q2 | $3.11M | Buy |
39,548
+4,430
| +13% | +$363K | 1.55% | 47 |
|
|
2024
Q1 | $3.06M | Buy |
35,118
+27,472
| +359% | +$2.34M | 1.56% | 37 |
|
|
2023
Q4 | $630K | Buy |
+7,646
| New | +$583K | 0.18% | 68 |
|
|
2023
Q2 | – | Sell |
-38,407
| Closed | -$3.1M | – | 624 |
|
|
2023
Q1 | $3.1M | Buy |
38,407
+5,152
| +15% | +$420K | 0.44% | 19 |
|
|
2022
Q4 | $2.58M | Buy |
33,255
+549
| +2% | +$44.5K | 0.41% | 25 |
|
|
2022
Q3 | $2.64M | Buy |
32,706
+4,455
| +16% | +$400K | 1.06% | 21 |
|
|
2022
Q2 | $2.54M | Buy |
28,251
+1,882
| +7% | +$191K | 0.84% | 23 |
|
|
2022
Q1 | $2.93M | Buy |
26,369
+6,014
| +30% | +$635K | 0.83% | 22 |
|
|
2021
Q4 | $2.11M | Sell |
20,355
-1,078
| -5% | -$125K | 0.57% | 41 |
|
|
2021
Q3 | $2.69M | Buy |
21,433
+3,041
| +17% | +$394K | 0.77% | 30 |
|
|
2021
Q2 | $2.28M | Buy |
18,392
+235
| +1% | +$29.5K | 0.79% | 29 |
|
|
2021
Q1 | $2.14M | Buy |
18,157
+1,389
| +8% | +$163K | 0.79% | 27 |
|
|
2020
Q4 | $1.96M | Buy |
16,768
+15
| +0.1% | +$1.65K | 0.9% | 23 |
|
|
2020
Q3 | $1.74M | Sell |
16,753
-31
| -0.2% | -$3.11K | 0.95% | 26 |
|
|
2020
Q2 | $1.54M | Buy |
16,784
+1,769
| +12% | +$170K | 0.86% | 29 |
|
|
2020
Q1 | $1.35M | Buy |
15,015
+12,066
| +409% | +$1.28M | 0.7% | 27 |
|
|
2019
Q4 | $335K | Buy |
2,949
+235
| +9% | +$25.8K | 0.21% | 42 |
|
|
2019
Q3 | $295K | Sell |
2,714
-11,771
| -81% | -$1.23M | 0.19% | 40 |
|
|
2019
Q2 | $1.41M | Buy |
+14,485
| New | +$1.32M | 0.63% | 36 |
|
|
2018
Q3 | – | Sell |
-10,219
| Closed | -$875K | – | 222 |
|
|
2018
Q2 | $875K | Buy |
+10,219
| New | +$854K | 0.83% | 28 |
|
|
2018
Q1 | – | Sell |
-10,044
| Closed | -$811K | – | 140 |
|
|
2017
Q4 | $811K | Buy |
+10,044
| New | +$804K | 0.84% | 32 |
|
Other funds holding MDT
Arlington Partners's MDT Position: Q3 2026 in Review
Arlington Partners sold out of Medtronic (MDT) in Q3 2026, closing a stake of 3,445 shares — an estimated $270K sold.
Arlington Partners first reported a position in MDT in Q4 2017 and held it in 28 quarters. The position peaked at $5.16M in Q3 2025. 774 funds tracked by Wall St. Rank hold MDT as of Q3 2026.
- Arlington Partners reported no remaining Medtronic position as of Q3 2026 after selling out during the quarter.
- Arlington Partners sold 3,445 Medtronic shares in Q3 2026, an estimated $270K.
- Arlington Partners first reported a position in Medtronic in Q4 2017 and held it in 28 quarters.
- Arlington Partners's Medtronic position peaked at $5.16M in Q3 2025.
- 774 funds tracked by Wall St. Rank held Medtronic as of Q3 2026.
Based on Arlington Partners's 13F filing for Q3 2026, filed 20 Oct 2026.